drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Antibody–drug conjugate targeting TROP2; upon internalization it releases deruxtecan, a topoisomerase I inhibitor, causing tumor DNA damage.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized anti‑TROP2 monoclonal antibody linked via a cleavable linker to deruxtecan (DXd), a topoisomerase I inhibitor. After binding TROP2 on tumor cells and internalization, the linker is cleaved to release DXd, which inhibits topoisomerase I, causing DNA damage and apoptosis; the membrane‑permeable payload can also exert a bystander effect.
drug_name
Datopotamab deruxtecan (Dato-DXd)
nct_id_drug_ref
NCT06103864